Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...

In the last few months of 2025, shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) went on an undeniable hot ...

The site, which will cost about €10.0 billion ($11.7 billion) to complete, will be the third-largest of the company’s Verbund ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or ...

"My pipeline in terms of number of IPOs at the SEC or working to get them into the SEC is bigger than I have ever had in my ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2026 to 2030 based on projected revenue and net income.

Eli Lilly and Company and Ventyx Biosciences, Inc., a San Diego-based clinical-stage biopharmaceutical company focused on ...

The terms of the agreement entail that Eli Lilly and Company (NYSE:LLY) would acquire all the outstanding shares of Ventyx ...

Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s ...

Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could ...

The US House advanced legislation to reinstate healthcare subsidies amid political tensions. Eli Lilly expands its portfolio ...

Fintel reports that on January 8, 2026, Wells Fargo downgraded their outlook for Ventyx Biosciences (NasdaqGS:VTYX) from ...